Format

Send to

Choose Destination
J Orthop Res. 2018 Jun;36(6):1581-1589. doi: 10.1002/jor.23819. Epub 2017 Dec 22.

CDK4 expression in chordoma: A potential therapeutic target.

Author information

1
UCLA Orthopaedic Surgery, Sarcoma Biology Laboratory, 615 Charles E Young Dr. South, Biomedical Sciences Research Building, Room 410, Los Angeles, CA 90095.
2
Department of Orthopaedics, the 2nd Xiangya Hospital of Central South University, 139 Renmin Road, Changsha, Hunan 410011, P.R. China.
3
Department of Orthopedic Surgery, Liu Hua Qiao Hospital, Guangzhou 510010, P.R. China.

Abstract

Chordomas are rare bone tumors and treatment is commonly based on a combination of surgery and radiotherapy. There is no standard chemotherapy treatment for chordoma. The aim of this study was to determine the expression of cyclin-dependent kinase 4 (CDK4) in chordoma and its therapeutic implications. We evaluated CDK4 expression both in chordoma cell lines and in chordoma tissues. Also, we investigated the functional roles of CDK4 in chordoma cell growth and proliferation. Furthermore, the therapeutic implications of targeting CDK4 in chordoma were evaluated. We found CDK4 highly expressed in chordoma cell lines and in a majority (97.7%) of chordoma tissues. Higher CDK4 expression correlated with metastasis and recurrence of chordoma. Treatment of chordoma cells using CDK4 inhibitor palbociclib could efficiently inhibit chordoma cells growth and proliferation. These data demonstrate that targeting CDK4 may be useful as a novel strategy in the treatment of chordoma. © 2017 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 36:1581-1589, 2018.

KEYWORDS:

CDK4; CDK6; chordoma; p16INK4A; palbociclib

PMID:
29194728
DOI:
10.1002/jor.23819

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center